

Accepted Manuscript

Hemophilia A Inhibitor Treatment: The Promise of Engineered T Cell Therapy

Kalpana Parvathaneni, Maha Abdeladhim, Kathleen P. Pratt, David W. Scott



PII: S1931-5244(17)30121-4

DOI: [10.1016/j.trsl.2017.06.002](https://doi.org/10.1016/j.trsl.2017.06.002)

Reference: TRSL 1159

To appear in: *Translational Research*

Received Date: 25 February 2017

Revised Date: 23 May 2017

Accepted Date: 5 June 2017

Please cite this article as: Parvathaneni K, Abdeladhim M, Pratt KP, Scott DW, Hemophilia A Inhibitor Treatment: The Promise of Engineered T Cell Therapy, *Translational Research* (2017), doi: 10.1016/j.trsl.2017.06.002.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Hemophilia A Inhibitor Treatment: The Promise of Engineered T Cell Therapy

Kalpana Parvathaneni, Maha Abdeladhim*, Kathleen P. Pratt and David W. Scott*

Department of Medicine, Uniformed Services University of Health Sciences
Bethesda, MD 20814.

* These authors contributed equally to this review.

Correspondence:

David W. Scott, PhD.

Department of Medicine,

The Uniformed Services University of Health Sciences,

Bethesda, MD 20814

David.Scott@usuhs.edu

Tel: 301-295-3618

Fax: 301-295-3557

Download English Version:

<https://daneshyari.com/en/article/5684961>

Download Persian Version:

<https://daneshyari.com/article/5684961>

[Daneshyari.com](https://daneshyari.com)